Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Amplified Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT00490139
What this trial is testing

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 8,381
Testing effectiveness (Phase 2)Active Not RecruitingNCT03379428
What this trial is testing

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsMalignant Neoplasm of Breast
US Oncology Research 34
Testing effectiveness (Phase 2)Study completedNCT00769470
What this trial is testing

Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery

Who this might be right for
Breast Cancer
Translational Oncology Research International 18
Testing effectiveness (Phase 2)Study completedNCT01670877
What this trial is testing

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine 56
Testing effectiveness (Phase 2)Looking for participantsNCT06726148
What this trial is testing

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsExtensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals 280
Testing effectiveness (Phase 2)Active Not RecruitingNCT06840483
What this trial is testing

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Who this might be right for
Breast Cancer
BicycleTx Limited 66
Testing effectiveness (Phase 2)Looking for participantsNCT06016387
What this trial is testing

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

Who this might be right for
HER2-positive Breast CancerLMD
Sunnybrook Health Sciences Centre 30
Post-approval studies (Phase 4)Looking for participantsNCT07195344
What this trial is testing

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Who this might be right for
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud 210
Testing effectiveness (Phase 2)Study completedNCT04366713
What this trial is testing

Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Who this might be right for
HER2 Amplified Breast Cancer
Puma Biotechnology, Inc. 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT05546268
What this trial is testing

Study of Oral MRT-2359 in Selected Cancer Patients

Who this might be right for
NSCLCSCLCHigh Grade Neuroendocrine Cancer+5 more
Monte Rosa Therapeutics, Inc 174
Testing effectiveness (Phase 2)Study completedNCT01128543
What this trial is testing

Lapatinib in Combination With Vinorelbine

Who this might be right for
Cancer
GlaxoSmithKline 29
Testing effectiveness (Phase 2)Study completedNCT02091960
What this trial is testing

Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Who this might be right for
HER2 AmplifiedAdvanced Breast CancerHuman Epidermal Growth Factor Receptor 2 (HER2)
Astellas Pharma Global Development, Inc. 103
Not applicableStudy completedNCT00097487
What this trial is testing

Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane

Who this might be right for
Breast CancerMetastases
Genentech, Inc. 1,000
Testing effectiveness (Phase 2)Study completedNCT02005887
What this trial is testing

TRial on the Endocrine Activity of Neoadjuvant Degarelix

Who this might be right for
Breast Cancer Invasive Nos
ETOP IBCSG Partners Foundation 51
Testing effectiveness (Phase 2)Study completedNCT01975142
What this trial is testing

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Who this might be right for
Metastatic Breast Cancer, HER2 Negative Primary Tumor
Institut Curie 155
Testing effectiveness (Phase 2)WithdrawnNCT01557764
What this trial is testing

Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Testing effectiveness (Phase 2)Ended earlyNCT03894007
What this trial is testing

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

Who this might be right for
Early-stage Breast CancerHER2-positive Breast Cancer
Renske Altena 6
Testing effectiveness (Phase 2)Study completedNCT01828021
What this trial is testing

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

Who this might be right for
Breast Cancer
MacroGenics 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT03820141
What this trial is testing

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Who this might be right for
Breast Cancer
The Methodist Hospital Research Institute 51
Next Page